DLBCL can affect people of any age ... It starts in places other than the lymph nodes (extranodal sites). There are gastric and non-gastric MALT lymphomas: The average age of people with MALT lymphoma ...

The triglyceride-glucose (TyG) index is an accurate and useful tool for prognostic assessment in diffuse large B-cell lymphoma (DLBCL), according to results published in Frontiers of Endocrinology. An ...

Clinicians can help reduce gastric cancer incidence and mortality in high-risk groups through endoscopic screening and surveillance of precancerous conditions, such as gastric intestinal ...

Histopathological examination diagnosed a triple-expressor gastric Diffuse Large B-Cell Lymphoma (DLBCL) [Bcl-2 focal (60%), Bcl-6 focal (40%), C-Myc (10%), CD10 focal (70%)]. The Ki-67 index was ...

Researchers identified nearly 50,000 patients diagnosed with DLBCL over a 15-year period to measure the impact of SES on 5-year overall survival (OS). Patients living in low SES regions had ...

These investigators assessed the potential benefit of a high-risk signature to evaluate the molecular drivers of primary treatment resistance in patients with DLBCL. A recent study published in ...

Overexpression of MYC and BCL2 in DLBCL is linked to increased CCL2 and CCR2, promoting M2 macrophage polarization and aggressiveness. Elevated CCL2 and CCR2 expression correlates with poor ...

One such lymphoma is DLBCL (diffuse large B-cell lymphoma), a prevalent form of NHL (non-Hodgkin lymphoma), arises when B-cells, the body's infection-fighting white blood cells, undergo abnormal ...

gastric lymphoma diffuse large B cell lymphoma (DLBCL) of the stomach Doctors often treat gastric lymphomas with chemotherapy or radiation therapy. Antibiotics may also help treat severe or ...

DLBCL can be cured in about half of all patients ... it might also be worth considering entering a clinical trial. Gastric (stomach) MALT lymphoma often occurs as a result of a chronic infection with ...

Roche’s up-and-coming Columvi has demonstrated it could save lives when used as a second-line therapy in diffuse large B-cell lymphoma (DLBCL). But the Swiss pharma still finds itself fielding ...